Asia Ceramics Share Discussion Threads

[hazl] 28/11/2024 23:20

In collaboration with the University of Salford and IntoUniversity, the University of Manchester played a pivotal role in launching a new learning centre aimed at supporting thousands of young people to achieve their academic and career ambitions.

Salford is the 18th most deprived local authority in England, out of 317, with latest figures suggesting 22% of children are living in poverty and pupils in the area now 22.9 months of learning behind their peers by the end of their GCSEs.

The centre has exceeded targets since opening, driven by a dedicated team that has supported over 1,500 young people, recruited students to Academic Support, established partnerships with local schools and run programmes through the holidays.

[hazl] 28/11/2024 23:14

In addition to keeping a close eye on gold, we’ve also been tracking all of the regional Fed surveys, which are showing a massive surge in optimism and future business conditions, especially for manufacturing but the service sector too. Consumers and businesses alike are much more upbeat about what the future holds. It would be wise to consider slowly shifting from consumer defensive to consumer discretionary in the year ahead. The same goes for rebalancing the portfolio to include less healthcare and more tech along with basic materials. Just be careful not to do it too early as there are still troubled waters ahead before we enter the promised land of a new American Golden Age.


Thanks to Ace

[hazl] 28/11/2024 23:07

Research Project of the Year: STEM

Groundbreaking research that led to the worlds-first bedside genetic test to prevent babies going deaf has also earned a nomination.

The research, led by Saint Mary’s Hospital, part of Manchester University NHS Foundation Trust (MFT), The University of Manchester and Manchester-based firm genedrive Plc, helped to develop the pioneering, rapid bedside genetic test which was piloted at MFT in 2022.

The technology could save the hearing of 180 babies in the UK every year and bring a saving of £5m to the NHS annually. The test is now being rolled-out in all Neonatal Intensive Care Units in Greater Manchester, with a hope that this will become part of routine clinical care across the UK.

[hazl] 26/11/2024 11:50

Undervalued I believe BBSN SOLG GDR.

[hazl] 26/11/2024 07:21

The parties to the Project Agreement will use their reasonable endeavours to contribute towards the successful Trials and to receipt of a final Letter of No Objection from Wärtsilä following 4,000 hours of bioMSAR™ testing, with:

· Quadrise providing equipment, additives and technical expertise; and

· MSC providing the trial vessel, MSC Leandra, necessary flag state approvals for the Trials and procuring professional monitoring services for the Trials; and

· Cargill providing the necessary feedstocks, transportation of fuels and operational and logistical support.



MAC2 have already received the required operating permits for installation of Quadrise equipment and have prepared the site. Following signature of the Project Agreement, final work to enable Quadrise equipment to be delivered to the MAC2 site can now be completed, enabling the Trials to commence before end Q1 2025.



In parallel, bilateral agreements, including a toll manufacturing agreement between Cargill and Quadrise in respect of fuel manufacture, can be finalised now that the outline commercial terms have been agreed in the Project Agreement.



Upon successful conclusion of the Trials, MSC, Cargill and Quadrise will negotiate and enter into a definitive long-term Commercial Agreement.

[hazl] 25/11/2024 19:58

Marine sector

The marine sector, specifically MSC, offers significant commercial opportunities for Quadrise. MSC currently consumes close to 10 million tonnes of fuel oil annually.

Shore Capital estimates Quadrise could charge approximately $50 per tonne for licensing its technology, potentially generating £400 million ($500 million) in annual revenues.

However, challenges remain. Negotiations with MSC are ongoing, and there is no certainty that the shipping giant will adopt Quadrise’s solution across its entire fleet.

With a market capitalisation of just over £40 million, Quadrise’s current valuation appears modest relative to its potential. Even a partial realisation of its projected revenues could significantly impact the company’s growth trajectory.

[hazl] 25/11/2024 19:56

Shore Capital estimates Quadrise could charge approximately $50 per tonne for licensing its technology, potentially generating £400 million ($500 million) in annual revenues.

[hazl] 25/11/2024 09:13

The purpose of this Agreement is to leverage the respective resources of Quadrise and Auramarine in emulsion fuels, biofuels and fuel systems to seek to offer innovative solutions that help to improve operational efficiencies and decarbonise energy-intensive applications, with a focus on the marine sector.

[hazl] 25/11/2024 08:42

QED today!

[hazl] 24/11/2024 11:39

In conclusion, Genedrive PLC has navigated a complex landscape in 2024 with a mix of achievements and challenges. The company's innovative products, strategic partnerships, and commitment to expanding its market reach are promising indicators of future success. While market volatility remains a concern, the long-term outlook for Genedrive appears positive, making it a company to watch closely as it continues to evolve in the rapidly changing healthcare diagnostics sector.

As we move forward, staying informed about Genedrive's developments and market conditions will be crucial for investors. With a focus on innovation and global health, Genedrive is poised to make significant contributions to the healthcare industry, potentially driving substantial value for its stakeholders.

[hazl] 24/11/2024 11:38

A key highlight of 2024 has been Genedrive's collaboration with global healthcare institutions. In June 2024, the company announced a partnership with the World Health Organization (WHO) to provide molecular diagnostics in low-resource settings. This initiative not only underscores Genedrive's commitment to global health but also opens new avenues for market expansion.

[hazl] 23/11/2024 13:19

The 24 month, PALOH-UK study, due to start in November 2024 will be co-led by Professor Bill Newman, Consultant in Genomic Medicine at the Manchester Centre for Genomic Medicine, Saint Mary’s Hospital and Professor of Translational Genomic Medicine at The University of Manchester.

[hazl] 17/11/2024 09:27

Alex Barnicoat
@AlexBarnicoat_
·
20h
🚨🇨🇳

AMERICA IS MAD

China just opened one of the world's largest shipping ports, in South America.

Here's a thread of everything you need to know:

(🧵 1/5)
Image
Alex Barnicoat
@AlexBarnicoat_
1. Where is this port?

The $3.5 billion port has just been opened in Chancay, Peru.

This port will be the new hub between South America and Asia, and has created a new shipping route called the "China Latin America Freight Route".

[hazl] 10/11/2024 18:19

Genedrive featured in UK Government Department for Business and Trade spotlight on UK genomics



genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that it has been featured in the UK Government Department for Business and Trade ("DBT") publication "UK Genomics Spotlight 2024: Celebrating success and looking ahead"



The document is available at The report highlights the UK's depth and breadth of expertise for export as world leaders in the field of genomics, as well as opportunities for investing in the UK. It describes the ecosystem which has enabled the delivery of genomic medicine in the UK and expertise in various national initiatives and programmes which are contributing to the genomics landscape of the future.



The DBT has produced the Genomics Spotlight 2024 to showcase the UK's expertise in genomics and latest developments that make the UK a hub for genomics business and investment, and has worked closely with the NHS, including NHS England and all three of the devolved nations, as well as encouraging input from several key organisations and companies in the UK.

[hazl] 04/11/2024 06:43

The 3D Reset” refers to the three “Ds” of decarbonisation, demographics and deglobalisation. We believe these ongoing trends have had and will continue to have massive long-term implications for the global economy. Taken together, the 3Ds are reshaping the investment landscape. Understanding the three Ds - how they affect the global economy, what that means for market volatility, and how active investors should be allocating their assets - might be the key to deciphering what comes next and where the opportunities are.
This energy transition will be expensive and drive inflationary tendencies, particularly given the amount of investment needed to bring innovation to scale.
greater nearshoring of key sectors, such as manufacturing, which in turn could have implications across a wide range of sectors and asset classes.
Changing demographics - specifically a predicted slowing of global population growth - will have a huge impact on inflation and economic growth as employers face pressure to compete for a tighter talent pool and maximise the efficiency of its existing workforce. Companies will also look to invest in productivity-boosting technology to protect profit margins, likely hastening the more widespread adoption of robotics and artificial intelligence.

[hazl] 04/11/2024 06:22

Chuckle the ignorance is bliss.